within Pharmacolibrary.Drugs.ATC.J;

model J05AF10
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.00023333333333333333,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.076,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.021500000000000002,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.239,
    k12             = 9.4,
    k21             = 9.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AF10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Entecavir is a nucleoside analogue with potent and selective activity against hepatitis B virus (HBV). It inhibits the HBV DNA polymerase, reducing viral replication. It is approved for the treatment of chronic hepatitis B infection in adults and pediatric patients over 2 years of age.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following single oral administration.</p><h4>References</h4><ol><li><p>Zhang, QH, et al., &amp; Davey, AK (2010). Food effect on the pharmacokinetics of entecavir from dispersible tablets following oral administration in healthy Chinese volunteers. <i>Arzneimittel-Forschung</i> 60(10) 640–644. DOI:<a href=\"https://doi.org/10.1055/s-0031-1296339\">10.1055/s-0031-1296339</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21125816/\">https://pubmed.ncbi.nlm.nih.gov/21125816</a></p></li><li><p>Yan, JH, et al., &amp; LaCreta, F (2006). Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. <i>Journal of clinical pharmacology</i> 46(11) 1250–1258. DOI:<a href=\"https://doi.org/10.1177/0091270006293304\">10.1177/0091270006293304</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17050790/\">https://pubmed.ncbi.nlm.nih.gov/17050790</a></p></li><li><p>Robinson, DM, et al., &amp; Plosker, GL (2006). Entecavir: a review of its use in chronic hepatitis B. <i>Drugs</i> 66(12) 1605–1624. DOI:<a href=\"https://doi.org/10.2165/00003495-200666120-00009\">10.2165/00003495-200666120-00009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16956310/\">https://pubmed.ncbi.nlm.nih.gov/16956310</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AF10;
